Fulminant lupus myositis: an exceptional case
DOI:
https://doi.org/10.32818/reccmi.a10n3a15Keywords:
systemic lupus erythematosus, lupus myositis, neuromuscular manifestations, respiratory failure, autoimmune diseasesAbstract
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease with a broad clinical spectrum. Among its manifestations, neuromuscular complications are rare and often underestimated. We present the case of a young patient whose SLE was complicated by fulminant myositis associated with severe central neurological involvement. Despite intensive immunosuppressive treatment, the course was rapidly unfavorable, resulting in death due to respiratory failure secondary to diaphragmatic dysfunction. This case highlights the rarity and severity of lupus myositis and emphasizes the importance of early diagnosis and aggressive therapeutic intervention.
Downloads
Metrics
References
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019; 71(9): 1400-12. doi: https://doi.org/10.1002/art.40930 (último acceso dic. 2025). DOI: https://doi.org/10.1002/art.40930
Bitencourt N, Solow E B, Wright T, Bermas B L. Inflammatory myositis in systemic lupus erythematosus: prevalence, clinical/laboratory and pathological features in a cohort of paediatric and adult patients. Clin Exp Rheumatol. 2020; 38(3): 563-70. doi: https://doi.org/10.1177/0961203320918021 (último acceso dic. 2025). DOI: https://doi.org/10.1177/0961203320918021
Salem TB, Hamrouni S, Ghorbel IB, Naceur I, Lamloum M, Houman MH. Caractéristiques cliniques, biologiques et immunologiques des myosites associées aux connectivites. Rev Med Interne. 2017; 38: A197. doi: https://doi.org/10.1016/j.revmed.2017.10.185 (último acceso dic. 2025). DOI: https://doi.org/10.1016/j.revmed.2017.10.185
Tiniakou E, Goldman D, Corse A, Mammen A, Petri MA. Clinical and histopathological features of myositis in systemic lupus erythematosus. Lupus Sci Med. 2022; 9(1): e000635. doi: https://doi.org/10.1136/lupus-2021-000635 (último acceso dic. 2025). DOI: https://doi.org/10.1136/lupus-2021-000635
Martens J, Demedts M, Vanmeenen MT, Dequeker J. Respiratory muscle dysfunction in systemic lupus erythematosus. Chest. 1983; 84(2): 170‑75. DOI: https://doi.org/10.1016/S0012-3692(15)33486-3
Appenzeller S, Bonilha L, Rio PA, Min Li L, Costallat LT, Cendes F. Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus. Neuroimage. 2007; 34(2): 694-701. doi: https://doi.org/10.1016/j.neuroimage.2006.09.029 (último acceso dic. 2025). DOI: https://doi.org/10.1016/j.neuroimage.2006.09.029
Mo S, Li Y, He J, Lin L. Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis. Front Med (Lausanne). 2024; 11: 1472019. doi: https://doi.org/10.3389/fmed.2024.1472019 (último acceso dic. 2025). DOI: https://doi.org/10.3389/fmed.2024.1472019
Guerreiro Castro S, Isenberg DA. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Ther Adv Musculoskelet Dis. 2017; 9(3): 75-85. doi: https://doi.org/10.1177/1759720X17690474 (último acceso dic. 2025). DOI: https://doi.org/10.1177/1759720X17690474
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Chaïmaâ Zeroual, Mina Moudatir, Khadija Echchilali, Hassan Elkabli
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
